Literature DB >> 16103103

Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.

A Francesca Setiadi1, Muriel D David, Susan S Chen, John Hiscott, Wilfred A Jefferies.   

Abstract

Expression of transporter associated with antigen processing (TAP) is often lost in metastatic carcinomas, resulting in defective antigen processing and presentation and escape of the cancer cells from immune surveillance. In this study, the nature of TAP deficiencies in tumors was investigated. By chromatin immunoprecipitation assay, we showed that the recruitment of RNA polymerase II to the TAP-1 gene was impaired in TAP-deficient cells derived from murine melanoma, prostate, and lung carcinomas, compared with TAP-expressing fibroblasts and lymphoma cells. This suggested that the deficiency in TAP-1 expression resulted, at least partially, from a relatively low level of transcription of the TAP-1 gene. Furthermore, levels of TAP-1 promoter activity, as assessed by stable transfections with a reporter construct containing the TAP-1 promoter, were relatively low in TAP-deficient cells. To examine genetic heritability of regulators of TAP-1 promoter activity, TAP- and MHC class I-deficient cells of H-2b origin were fused with wild-type fibroblasts of H-2k origin. Fusion with TAP-expressing cells complemented the low levels of TAP-1 promoter activity in TAP-deficient cells. However, these fused cells exhibited lower levels of TAP-1 mRNA and H-2k than unfused fibroblasts. Further analysis showed that TAP-1 mRNA stability was lower in fused carcinoma fibroblasts than in unfused fibroblasts. Based on these results, we propose that TAP deficiency in many carcinomas is caused by a decrease in activity/expression of trans-acting factors regulating TAP-1 promoter activity, as well as a decrease in TAP-1 mRNA stability. These results have significant implications for understanding immune evasion mechanisms in tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103103     DOI: 10.1158/0008-5472.CAN-03-3734

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Authors:  Michael S Leibowitz; Pedro A Andrade Filho; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2011-01-05       Impact factor: 6.968

2.  Epigenetic control of the immune escape mechanisms in malignant carcinomas.

Authors:  A Francesca Setiadi; Muriel D David; Robyn P Seipp; Jennifer A Hartikainen; Rayshad Gopaul; Wilfred A Jefferies
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

3.  CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.

Authors:  Aristides Moschonas; Maria Kouraki; Pauline G Knox; Efstathia Thymiakou; Dimitris Kardassis; Aristides G Eliopoulos
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

4.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

5.  Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis.

Authors:  Iryna Saranchova; Jeffrey Han; Rysa Zaman; Hitesh Arora; Hui Huang; Franz Fenninger; Kyung Bok Choi; Lonna Munro; Cheryl G Pfeifer; Ian Welch; Fumio Takei; Wilfred A Jefferies
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

6.  Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.

Authors:  Adviti Naik; Remy Thomas; Ghaneya Al-Khadairi; Rim Bacha; Wouter Hendrickx; Julie Decock
Journal:  J Cell Mol Med       Date:  2021-10-06       Impact factor: 5.310

7.  Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.

Authors:  Iryna Saranchova; Jeffrey Han; Hui Huang; Franz Fenninger; Kyung Bok Choi; Lonna Munro; Cheryl Pfeifer; Ian Welch; Alexander W Wyatt; Ladan Fazli; Martin E Gleave; Wilfred A Jefferies
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.